Mothers' human papilloma virus knowledge and willingness to vaccinate their adolescent daughters in Lagos, Nigeria

International Journal of Women's Health

Volumn 5, Issue 1, 2013, Pages 371-377

  Ezenwa, Beatrice N ^a   Balogun, Mobolanle R ^b   Okafor, Ifeoma P ^b  

^a Nigerian Army Reference Hospital   (Nigeria)

^b UNIVERSITY OF LAGOS   (Nigeria)

Author keywords

HPV; Nigeria; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; COMMUNITY SAMPLE; CROSS-SECTIONAL STUDY; DESCRIPTIVE RESEARCH; DISEASE ASSOCIATION; DRUG COST; EDUCATIONAL STATUS; FEMALE; HEALTH BEHAVIOR; HEALTH CARE ACCESS; HEALTH EDUCATION; HEALTH SURVEY; HUMAN; MATERNAL ATTITUDE; NIGERIA; PAPILLOMAVIRUS INFECTION; QUESTIONNAIRE; UNSAFE SEX; UTERINE CERVIX CANCER; VACCINATION; WOMEN'S HEALTH;

EID: 84880101075     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S44483     Document Type: Article

References (37)

1. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specifc HPV infections in female university students. Cancer Epidemiol Biomarkers Prev. 2003;12(6):485-490.
2. Di Giuseppe G, Abbate R, Liguori G, Albano L, Angelillo IF. Human papillomavirus and vaccination: knowledge, attitudes, and behavioural intention in adolescents and young women in Italy. Br J Cancer. 2008;99(2):225-229.
3. Dahlstrom LA, Tran TN, Lundholm C, Young C, Sundström K, Sparén P. Attitudes to HPV vaccination among parents of children aged 12-15 years-a population-based survey in Sweden. Int J Cancer. 2010;126(2):500-507.
4. Trim K, Nagji N, Elit L, Roy K. Parental knowledge, attitudes, and behaviors towards human papillomavirus vaccination for their children: a systematic review from 2001 to 2011. Obstet Gynecol Int. 2012;2012: 921236.
5. Anorlu RI. Cervical cancer: the sub-Saharan African perspective. Reprod Health Matters. 2008;16(32):41-49.
6. Burk RD, Kelly P, Feldman J, et al. Declining prevalence of cervicova-ginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis. 1996;23(4):333-341.
7. World Health Organization. Information Centre on HPV and Cervical Cancer. Human Papillomavirus and Related Cancers in Nigeria. Summary Report 2010. Accessed June 2, 2012.
8. Rama CH, Villa LL, Pagliusi S, et al. Awareness and knowledge of HPV, cervical cancer, and vaccines in young women after frst delivery in Sao Paulo Brazil - a cross-sectional study. BMC Womens Health. 2010;10:35-41.
9. Makwe CC, Anorlu RI. Knowledge of and attitude toward human pap-illomavirus infection and vaccines among female nurses at a tertiary hospital in Nigeria. Int J Womens Health. 2011;3:313-317.
10. Nnodu O, Erinosho L, Jamda M, Olaniyi O, Adelaiye R, Lawson L, et al. Knowledge and Attitudes towards cervical cancer and human papillomavirus: a Nigerian pilot study. Afr J Reprod Health. 2010;14(1):95-108.
11. Insinga R P, Glass AG, Rush BB. The health care costs of cervical human papillomavirus - related disease. Am J Obst Gynecol. 2004;191(1):114-120.
12. Zhou J, Sun X Y, Stenzel DJ, Frazer IH. Expression of vaccinia recombi-nant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991;185(1):251-257.
13. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. Virology. 1993;67(1):315-322.
14. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol. 2004;2(4):343-347.
15. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995;92(25): 11553-11557.
16. Jansen KU, Rosolowsky M, Schultz LD, et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine. 1995;13(16):1509-1514.
17. Pastrana DV, Vass WC, Lowy DR, Schiller JT. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology. 2001;279(1):361-369.
18. Soper D. Reducing the health burden of HPV infection through vaccination. Infect Dis Obstet Gynecol. 2006;2006 Suppl:83084.
19. Castellsagué X, Klaustermeier J, Carrilho C. Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: burden and potential for prevention. Int J Cancer. 2008;122(8): 1901-1904.
20. Tialma WA, van Damme P. Who should be vaccinated against human papillomavirus? Int J Cynecol Cancer. 2006;16(4):1498-1499.
21. Markowitz LE, Dunne EF, Saraiya M, Lawson H W, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2): 1-24.
22. Perkins RB, Langrish SM, Cotton DJ, Simon CJ. Maternal support for human papillomavirus vaccination in Honduras. J Womens Health (Larchmt). 2011;20(1):85-90.
23. Ben Natan M, Aharon O, Pclickshvili S, Gurman V. Attitude of Israeli mothers with vaccination of their daughters against human papilloma virus. J Pediatr Nurs. 2011;26(1):70-77.
24. Nøhr B, Munk C, Tryggvadottir L, et al. Awareness of human papillomavirus in a cohort of nearly 70,000 women from four Nordic countries. Acta Obstet Gynecol Scand. 2008;87(10):1048-1054.
25. Tiro JA, Meissner HI, Kobrin S, Chollette V. What do women in the US know about human papillomavirus and cervical cancer? Cancer Epidemiol Biomarkers Prev. 2007;16(2):288-294.
26. Marlow LA, Waller J, Wardle J. Public awareness that HPV is a risk factor for cervical cancer. Br J Cancer. 2007;97(5):691-694.
27. Al-Dubai SA, Alshagga MA, Al-Naggar RA, et al. Knowledge, attitudes and barriers for human papilloma virus (HPV) vaccines among Malaysian women. Asian Pac J Cancer Prev. 2010;11(4):887-892.
28. Dell DL, Chen H, Ahmad F, Stewart DE. Knowledge about human papillomavirus among adolescents. Obstet Gynecol. 2000;96(5 Pt 1): 653-656.
29. Poland GA, Jacobson RM, Koutsky LA, et al. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. Mayo Clin Proc. 2005;80(5):601-610.
30. Dinh TA, Rosenthal SL, Doan ED, et al. Attitudes of mothers in Da Nang, Vietnam toward a human papillomavirus vaccine. J Adolesc Health. 2007;40(6):559-563.
31. Oguntola S. Vaccination: easy way out of cervical cancer. The Nigerian Tribune. 14 October 2011. Available from: http://www.tribune.com.ng/index.php/yourhealth/29655. Accessed June 20, 2012.
32. Woodhall SC, Lehtinen M, Verho T, Huhtala H, Hokkanen M, Kosunen E. Anticipated acceptance of HPV vaccination at the baseline of implementation: a survey of parental and adolescent knowledge and attitudes in Finland. J Adolesc Health. 2007;40(5):466-469.
33. Balogun MR, Odukoya OO, Oyediran MA, Ujomu PI. Cervical cancer awareness and preventive practices: a challenge for female urban slum dwellers in Lagos, Nigeria. Afr J Reprod Health. 2012;16(1): 75-82.
34. Sherris J, Friedman A, Wittet S, Philip D, Steben M, Saraiya M. Chapter 25: education, training, and communication for HPV vaccines. Vaccine. 2006;24 Suppl 3:S3/210-S3/218.
35. Federal Republic of Nigeria Official Gazette No 24, Vol 94, B 175-198. Legal notice on publication of Details of the breakdown of the National and State Provincial Totals of 2006 Census. Lagos, Nigeria. May 15, 2007.
36. Nwagwu WE. The Internet as a source of reproductive health information among adolescent girls in an urban city in Nigeria. BMC Public Health. 2007;7:354.
37. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep. 2011;60(1):13-15.